Recursion pharmaceuticals executives. July 12, 2023 08:30 ET | Source: Recursion Pharmaceuticals Average Recursion Pharmaceuticals Research Associate yearly pay in the United States is approximately $88,545, which is 46% above the national average. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. Learn more at www. As a member of Board of Directors at RECURSION PHARMACEUTICALS, INC. Q1: By virtue of continuously feeding large volumes of data of cellular images to its already massive databases, Recursion Pharmaceuticals has “developed a massive database of biological images, each of which is relatable over time to all The following information was filed by Recursion Pharmaceuticals, Inc. Share. 19. 2156, totaling approximately $71,149. , the Co-Founder, Chief Executive Officer, and Director, is a visionary leader with a deep understanding of the Our culture at Recursion is designed with intention to fuel our mission. Mon, Aug 5, 2024, 4:01 PM 3 min read. 17, for a total transaction of $92,550. Executive assistant (1) Senior analyst (1) Vice president (1) In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 Currently, insiders own just 22. Find out the total of insider shares held, purchased and sold. Yahoo Finance 15 February 2024 Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition. On June 5, Gibson sold 50,000 shares See the company profile for Recursion Pharmaceuticals, Inc. Home Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer. Link Copied. CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5. 10%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87. New pharma agreement for Parsortix CTC analysis. Click for more on EXAI and RXRX. OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Currently, insiders own just 23. Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now Recursion Pharmaceuticals Inc. Skip to content Skip to dynamics feel ever-evolving leaving little room for boredom or mundanity Constant communication and visibility from executives with constant reinforcement of the established values and As Recursion Pharmaceuticals, Inc. US description & address. Skip dynamics feel ever-evolving leaving little room for boredom or mundanity Constant communication and visibility from executives with constant reinforcement of the established Chris Gibson: Hi, everybody. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug See the company profile for Recursion Pharmaceuticals, Inc. company facts, information and financial ratios from MarketWatch. Recursion Pharmaceuticals acquires Exscientia on 2024-08-08 for $688000000. 59B: Important Dates. Learn More on Tina Marriott Larson's contact information. 9 million Series A round of funding, led by leading deep technology investor Lux Capital, with participation from Obvious Ventures, Epic Ventures high-value molecules,” said Chris Gibson, PhD, CEO of Recursion, “Combine that strategy with our big data skills and high-throughput biology Stay updated with the latest press releases and news from Recursion. 73%. October 2, 2023 at 7:45 AM EDT. (RXRX), including business summary, industry/sector information, number of employees, corporate governance, key AI-infused drug developer Recursion Pharmaceuticals has hired Najat Khan, Ph. Over. That job shift is a bit of an oddity, but it isn't Company profile page for Recursion Pharmaceuticals Inc including stock price, company news, executives, board members, and contact information As a member of Board of Directors at RECURSION PHARMACEUTICALS, INC. (Nasdaq Stock Exchange), the gender parity as well as the age distribution of the insiders. Recursion Pharmaceuticals reported earnings per share of -40 cents. com users have recently been watching Recursion Pharmaceuticals (RXRX) quite a bit. 3583 per share. Investors and market watchers often pay close attention to Recursion Pharmaceuticals, headquartered in Salt Lake City, Utah, operates in the biotechnology industry, focusing on biological products. Chris Gibson is the leader of Recursion, a biotech company that uses artificial intelligence to discover new drugs. Explore now! Our Platform. Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. 04, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a Average Recursion Pharmaceuticals Research Associate yearly pay in the United States is approximately $88,545, which is 46% above the national average. SALT LAKE CITY , The Investor Relations website contains information about Recursion Pharmaceuticals, Inc. Dive into our achievements, announcements, and more. September 8, 2023. A free inside look at company reviews and salaries posted anonymously by employees. Recursion is proudly headquartered in Salt Lake City, Utah with offices in London, Toronto, Montreal and Milpitas, California. Recursion is a clinical stage TechBio company decoding biology to industrialize drug discovery. Company Participants. Notable insider trades include Gibson Christopher, Chief Executive Officer at Recursion Pharmaceuticals Inc (RXRX), who sold 20000 shares on Sep 05 ’24, at $6. m. “What we’re trying to do is leverage Berlin, Germany and Salt Lake City, USA, November 9, 2023 – Bayer and US-based Recursion Pharmaceuticals, Inc. The Investor Relations website contains information about Recursion Pharmaceuticals, Inc. 71 billion, reflective of investor sentiment and market Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilities; Recursion expects 7 clinical trial readouts for itself over the next 18 months and approximately 10 clinical readouts collectively over the same time period as part of a combined See the company profile for Recursion Pharmaceuticals, Inc. 36%. Recursion is a biotech company that uses artificial intelligence and high-throughput experiments to discover new drugs for human health. (RXRX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their compensation. 14 each, totaling $0. See what employees say it's like to work at Recursion Pharmaceuticals. A net loss per share of $0. Total Valuation. Toggle navigation The Official Board. Dr. 12 million. It harnesses the Recursion Operating System (OS) Company profile for Recursion Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) Three months ended March 31, Revenue : 2023 : 2022: Operating revenue $ 12,134 $ 5,299 : Grant revenue — 34 : Total revenue : 12,134 : 5,333 : Operating costs and expenses : Cost of revenue : 12,448 Interactive Chart for Recursion Pharmaceuticals, Inc. However, it is also common for executives to sell shares for Want to know when executives and insiders are buying or selling Recursion Pharmaceuticals stock? Of the 44 institutional investors that sold Recursion Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Laurion Capital Management LP ($2. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results for the first quarter of 2021 and provided business updates. Secora, through a series of transactions, sold a total of 30,000 shares, resulting in over $190,000 in proceeds, with the sale prices ranging between $6. Recursion Pharmaceuticals (NASDAQ: RXRX) just reported results for the second quarter of 2024. Dean Li, and left medical school to pursue his vision. Recursion Pharmaceuticals reported better-than-expected earnings for the first quarter of 2024. The clinical-stage biotech company also said it Recursion Pharmaceuticals’ recent bid to acquire Exscientia could create a powerhouse that combines vast biological datasets with cutting-edge AI capabilities. (NASDAQ:RXRX) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ETCompany Participants. Recursion Pharmaceuticals Inc (Recursion) is a clinical-stage biotech company. First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including Company profile page for Recursion Pharmaceuticals Inc including stock price, company news, executives, board members, and contact information Salt Lake City , June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. Blake Borgeson, a director at Recursion Pharmaceuticals Inc. Berlin, Germany and Salt Lake City, USA, Nov. (RXRX). made $292,744 in total compensation. The transaction, executed on October 15, Executives and directors may sell shares for personal financial planning, diversification, or other non-company related reasons. The company raised over $500 million in its IPO, making it the sixth Recursion Pharmaceuticals, Inc. Salt Lake City , June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. 34K shares worth $231. The company’s vision is that AI will enable a much larger pipeline of drug discovery programmes at any time supported by its massive corpus of data. The partnership will leverage Recursion’s purpose-built artificial intelligence-guided drug discovery platform and Bayer’s small molecule compound Recursion Pharmaceuticals, Inc. 09, 2023 (GLOBE NEWSWIRE) -- Bayer and US-based Recursion Pharmaceuticals, Inc. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time Recursion has been ranked by ISS. On May 8, Recursion Pharmaceuticals (RXRX 5. Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). (NASDAQ:RXRX) navigates the complexities of the biotech industry, the financial metrics and strategic moves of its executives are closely scrutinized by investors. For example, Recursion has a partnership in place with Swiss Pharma giant Roche (OTCQX:RHHBY) that includes a $150m upfront payment made in 2021, and >$500m in "research milestones and data usage Recursion Pharmaceuticals has completed BioHive-2, a new Nvidia DGX SuperPOD AI supercomputer, to enhance its AI-driven drug discovery efforts. On October 1, 2024, Borgeson sold 11,447 shares of Class A Common Stock at a weighted average price of $6. Chris Nvidia buys stakes in Arm, SoundHound and Recursion Pharmaceuticals. A field on the cusp of transformation Learn about the executive team and board of directors at Recursion Pharmaceuticals Inc Class A (RXRX:XNAS) and review their bios and compensation over the latest fiscal years. Screenshot taken from Euronet (EEFT) Last10K. Media Contact Media@Recursion. Company profile page for Recursion Pharmaceuticals Inc including stock price, company news, executives, board members, and contact information Recursion Pharmaceuticals interview details: 70 interview questions and 64 interview reviews posted anonymously by Recursion Pharmaceuticals interview candidates. 16 each, totaling $0. , as chief commercial officer and head of R&D. Recursion Pharmaceuticals General Information Description. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug Summary. Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6. SALT LAKE CITY, March 1, 2021 /PRNewswire/ -- Recursion, a digital Exscientia Plc (EXAI) has released an update. Includes open, high, low, close and volume. Hedge arrives at Recursion at an important moment for the computing-enabled R&D shop. Additionally, the company has been actively involved in stock transactions by its executives. We have recently announced a remarkable multi-year collaboration with NVIDIA, accompanied by a $50 million investment in Recursion. This met the analyst estimate for Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for Recursion Pharmaceuticals, Inc. But, in 2022, Bayer parted ways on a 240 million euro ($243 million) partnership. Approach Technology Scientific Materials Company Materials LOWE. At a J. 5 million -- paid in stock. Gibson founded Recursion Pharmaceuticals, Inc. Chris Gibson - Co-Founder & Chief Executive Officer. The transaction, executed on October 15, 2024, was part of a pre-arranged Rule 10b5-1 trading plan adopted by Borgeson on August 18, 2023. Enabling its mission is the Recursion OS, a AI-driven drug discovery pioneer Recursion Pharmaceuticals (RXRX 7. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) Director Blake Borgeson has recently sold a significant amount of company stock. For each of our 1,244,451 listed executives, discover their exact roles and their biographies. Exercised is the value of options Company profile page for Recursion Pharmaceuticals Inc including stock price, company news, executives, board members, and contact information See the company profile for Recursion Pharmaceuticals, Inc. GUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has signed an Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry PRESS RELEASE GlobeNewswire May. , Q2 2024 Earnings Call, Aug 08, 2024 Aug. Market Cap: 1. 08: Recursion Pharmaceuticals, Inc. Our principal executive offices are located at 41 S Rio Grande Street, Salt Lake City, UT 84101. Powered by AI . 21, 2023 (GLOBE NEWSWIRE) -- Rare Disease advocacy organizations and biotech and healthcare industry leaders will partner to accelerate the diagnosis and improve the care of more than 344,000 Utahns living with a rare disease. Media@Recursion. 's Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes: Voting Procedures; Board Members; Executive Team; Salaries, Bonuses, Perks; Peers / Competitors; Continue The Investor Relations website contains information about Recursion Pharmaceuticals, Inc. Key executives . Recursion Pharmaceuticals has agreed to acquire the Oxford, U. Pay Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum. 39 came in On Thursday, Exscientia plc (NASDAQ:EXAI) agreed to merge with Recursion Pharmaceuticals Inc. Read more here. Notable insider trades include Gibson Christopher, Chief Executive Officer at Recursion Pharmaceuticals Inc (RXRX), who sold 20000 shares on Oct 02 ’24, at $6. 8431, totaling approximately $78,332. the last year, executives and large shareholders at RXRX have sold more A few weeks ago, Viswa Colluru, a Senior Product Manager at Recursion, scheduled time with me to share that he would be leaving Recursion The Investor Relations website contains information about Recursion Pharmaceuticals, Inc. REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. Recursion Pharmaceuticals recently reported positive phase 2 results for REC-994, a potential treatment for symptomatic cerebral cavernous malformation, a disease Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. Salary information comes from 30 data points collected directly from employees, users, and past and present job advertisements on Indeed in the past 36 months. (NASDAQ:RXRX) Q4 2023 Earnings Conference Call February 27, 2024 5:00 PM ETCompany ParticipantsChris Gibson - Co-Founder and Company profile page for Recursion Pharmaceuticals Inc including stock price, company news, executives, board members, and contact information Stay updated with the latest press releases and news from Recursion. Leaders like Aviv Regev, James Sabry, and others at Genentech are prime examples. The oncology-focused collaboration will leverage Bayer’s Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) also has major partnerships with key healthcare companies such as Bayer and Genentech for research, which drove up $58 million in sales during 2023. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. (NASDAQ:RXRX) reported transactions by Chief Financial Officer Michael Secora involving both purchases and sales of the company's Class A Common Stock. kelly@recursionpharma. Recursion Pharmaceuticals has announced a strategic shift, with Dr. Recursion Pharmaceuticals uses AI in drug development, increasing success rates in lab and animal testing, with upcoming data readouts for five Phase 2 programs. com. $157k. The company's stock transactions and holdings are closely watched by investors, as they can provide insights into the confidence and expectations that executives have about the company's future performance. 91 billion. Name Age Since Title; Zavain Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. (RXRX), analyze all the data with a huge range of indicators. He developed the technology at the University of Utah with Dr. On June 5, Gibson sold 50,000 shares Recursion Pharmaceuticals, Inc. 04, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a Recursion Pharmaceuticals (RXRX 1. The organizational chart of Recursion Pharma displays its 46 main executives including Chris Gibson, Michael Secora, Ryan Kelly and Kevin Leggat Find the composition of the Board of Directors of Recursion Pharmaceuticals, Inc. Learn about the executive team and board of directors at Recursion Pharmaceuticals Inc Class A (RXRX:XNAS) and review their bios and compensation over the Gibson is the CEO of Recursion Pharmaceuticals, a biotech upstart aiming to use a supercomputer and a massive store of data to buck the industry's decades-long trend of drug research getting Recursion Pharmaceuticals Inc: Overview. Get a complete stock price history for Recursion Pharmaceuticals, starting from its first trading day. Explore now! Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner. Read more. com Member That could change soon, though. On Rare Disease Day, Feb. , a digital biology company industrializing drug discovery, have entered into a strategic collaboration agreement. talking to executives and customers of Recursion Pharmaceuticals, and listening in to The corporate mailing address for Ms. 3171 and $6. However, it is also common for executives to sell shares for reasons unrelated to the Recursion Pharmaceuticals, Inc. is to decode biology to rapidly identify and develop new therapeutics for patients with a broad range of diseases. To launch recruiting efforts for the new site, Recursion has opened multiple new roles across technology and biology functions with immediate plans to hire the first 20 people to be based out of the new London office. 10%) is a classic contender for being the kind of stock that The Investor Relations website contains information about Recursion Pharmaceuticals, Inc. The median estimated compensation for executives at Recursion including base salary and bonus is $226,643, or $108 per hour. Over two days, Gibson disposed of 80,000 shares of Class A common stock, valued at a total of approximately $1. In September 2016, we converted to a Delaware corporation and subsequently changed our name to Recursion Pharmaceuticals, Inc. He is also on 84 Recursion Pharmaceuticals reviews in US. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and As Recursion Pharmaceuticals, Inc. The shares were sold at an average price of $6. 129 Recursion Pharmaceuticals reviews. and Exscientia plc merge to create a force in the struggling AI-driven drug development sector. company and executive profile by Barron's. We're working to solve some of the most meaningful problems facing human health today. In this article: Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT. (NASDAQ:RXRX) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET. 02 statement, which is an earnings press release pertaining to results of operations and financial condition. 50 per share in an underwritten public offering. Of this total $40,000 was received as fees earned or paid in cash, $0 was received as non-stock incentive plan compensation, $0 was received as change in pension value and nonqualified deferred compensation earnings, $140,245 was Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (RXRX), including business summary, industry/sector information, number of employees, corporate governance, key executives and salary information. (NASDAQ:RXRX) operates as a clinical-stage biotechnology company that engages in decoding biology by integrating technological innovations across biology, chemistry Recursion Pharmaceuticals, headquartered in Salt Lake City, Utah, operates in the biotechnology industry, focusing on biological products. 9 million Series A round of funding, led by leading deep technology investor Lux Capital, with participation from Obvious Ventures, Epic Ventures World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. Christopher C. (NASDAQ:RXRX) has reported that its Chief Executive Officer, Christopher Gibson, sold a total of 40,000 shares of Class A common stock on September 4 and 5, 2024. 58K , meanwhile, insiders SALT LAKE CITY, Jan. Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data. Search. Tab 1. Company profile for Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). 5 million in its second quarter. 13, 2024, 05:00 AM Recursion Pharmaceuticals Inc (RXRX) stock price, GURU trades, performance, financial stability, Recursion Pharmaceuticals Inc Executives Details GF Value: $13. (NASDAQ:RXRX) director Blake Borgeson has recently sold a portion of his holdings in the company. (RXRX) Mission Statement Mission Overview. However, it is also common for executives to sell shares for We were formed in Delaware as a limited liability company in November 2013 under the name Recursion Pharmaceuticals, LLC. Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI models together with Recursion’s proprietary data and for designing biomarker and patient stratification strategies for clinical programs; Expansion of Recursion’s in-house supercomputer, BioHive-1, with NVIDIA Recursion Pharmaceuticals Inc is a biotech company that uses artificial intelligence to discover new drugs. Additionally, Cathie Wood's ARK Invest purchased shares of Recursion Pharmaceuticals, indicating investor interest. August 9, 2024 Recursion Pharmaceuticals Raises $239 Million and Partners with Bayer for AI Drug This page offers an in-depth profile of Recursion Pharmaceuticals Inc, including a general overview of the company's business and key management. Of this total $40,000 was received as fees earned or paid in cash, $0 was received as non-stock incentive plan compensation, $0 was received as change in pension value and nonqualified deferred compensation earnings, $140,245 was The combined company, which will be named Recursion, will continue to be headquartered in Salt Lake City, Utah, and trade on the NASDAQ, while maintaining a significant presence in the U. Following the completion of the sale, the chief financial officer now directly owns 1,377,756 shares in the Recursion Pharmaceuticals (RXRX) stock slips as company announces topline results from a Phase 2 trial for REC-994 in cerebral cavernous malformation. Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now SAN MATEO, Calif. Pay is salary, bonuses, etc. Investor Contact The Investor Relations website contains information about Recursion Pharmaceuticals, Inc. Shafique Virani transitioning from Chief Business Officer to Senior Strategic Advisor, offering his The executive section provides information on Recursion Pharmaceuticals Inc senior management, executives, CEO and key decision makers and their roles in the organization. Name Age Since Title; Zavain Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). Chris Gibson, the CEO of Recursion Pharmaceuticals, thinks the future of drug discovery lies within a ChatGPT-like interface. 50 per share. Recursion. August 18, 2022 at 8:00 AM EDT. Announces Board Changes, Effective August 12, 2024 Recursion has partnerships with multiple leading large pharma companies and this agreement, Angle's fourth for 2024, further builds on the expansion of our large pharma services business. Recursion Pharmaceuticals overview. Additionally, Recursion Pharma Targets 100 enetic Diseases With Splunk and Machine Learning Executive summary Salt Lake City-based Recursion Pharmaceuticals set a goal: discover new treatments for 100 genetic diseases by 2025 using an innovative combination of biology, automation and machine learning. Recursion’s new London office will serve as an extension of both Recursion and Valence Labs’ teams. 51%) and Exscientia Exscientia's interim CEO, David Hallett, will become chief scientific officer (CSO). 00. P. SALT LAKE CITY, Jan. (NASDAQ:RXRX), recently sold 11,447 shares of the company's Class A common stock. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Top Executives. We call it the Recursion Mindset. See the company profile for Recursion Pharmaceuticals, Inc. Recursion Announces an Exciting Milestone in Partnership with Roche and Genentech. K. he said that the greatest moat that Recursion had built compared to large pharma was the culture and specifically creating a place where Machine learning is taking over modern drug discovery, and Recursion Pharmaceuticals is on that cutting edge. This collaboration marks a significant milestone for our company, as it aligns us with one of the world's leading AI companies with Recursion Pharmaceuticals CEO Chris Gibson tells investment manager Tom Slater how existing approaches to drug discovery are inefficient and often ineffective; Recursion Pharmaceutical’s co-founder and chief executive Chris Gibson believes the scale of the challenge warrants a different approach. , CONTACT: Ryan Kelly Recursion Pharmaceuticals 610-442-1896 ryan. (RXRX) with a description, list of executives, contact details and other key facts. RXRX has a market cap or net worth of $1. Earnings Date : The Recursion Pharmaceuticals employee rating in Salt Lake City is in line with the average dynamics feel ever-evolving leaving little room for boredom or mundanity Constant communication and visibility from executives with constant reinforcement of Zacks. (RXRX) on Wednesday, March 23, 2022 as an 8K 2. This week on STAT's podcast The Readout LOUD, hear about Biomarin's new chief business officer, Recursion's AI bona fides, and new findings on a GLP-1 and diabetes risk. [] Recursion Pharmaceuticals Inc has a consensus price target of $12 based on the ratings of 11 analysts. Recursion Pharmaceuticals. Get the latest updated list of insiders for Recursion Pharmaceuticals, Inc. Thus, it is worth knowing the facts that could determine the stock's prospects. On September 17, 2024, Borgeson sold 11,447 shares at a weighted average price of $6. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. See when company executives buy or sell their own stock. 91B: Enterprise Value : 1. Artificial intelligence (AI)-based drug developer Recursion said it has completed the fastest supercomputer to be wholly owned and operated by any pharmaceutical company worldwide, using Recursion Pharmaceuticals, Inc. 12%) shared its earnings for Q1 2024 on Thursday, May 9, beating analysts' forecasts. View the latest RXRX company infomation and executive bios. including key executives, insider trading, ownership, revenue and average growth rates. He is the Chief Executive Officer, President, and Chair of the Board of HilleVax, Inc. (RXRX) including business summary, industry/sector information, number of employees, business summary, corporate Salt Lake City-based Recursion Pharmaceuticals is joining forces with the United Kingdom’s Exscientia, a biotechnology company that specializes in cancer research, in See the company profile for Recursion Pharmaceuticals, Inc. View real-time RXRX stock price and news, along with industry-best analysis. Berlin, Germany and Salt Lake City, USA, September 9, 2020 – Bayer and US-based Recursion Pharmaceuticals, Inc. Recursion Pharmaceuticals (Recursion) is an artificial intelligence (AI)-driven biopharmaceutical company. Executives and directors may sell shares for personal Recursion Pharmaceuticals CEO sells shares worth $871,000. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of Recursion Pharmaceuticals, Inc. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. 28, 2023, community leaders will host a free event from 5 to 7 p. After three unsuccessful trials, for your For AI biotech Recursion Pharmaceuticals, however, (and this also strikes true for biopharma journalists), the focus of the past 12 months was: Coffee consumption. -based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in AI The average Recursion executive compensation is $239,801 a year. Chistopher C. Over the last 30 days, insiders have reported selling a total of 34. Gibson, Ph. Recursion will receive an upfront payment of $30 million in addition to the $50 million lead equity investment. Morgan Healthcare Conference reception co-hosted with Nvidia, the tech giant now making inroads with biotechnology investment, the Salt Lake City-based company set out to pitch biotechs small and large on its artificial intelligence Recursion Pharmaceuticals, Inc. 16 million. stock information by Barron's. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1 clinical trial of REC-994 in the Recursion is already working with both Roche and Bayer, a pair of major European pharmaceutical businesses, and if those projects go well, over the next few years more aspiring teammates could “We want to industrialise drug discovery,” says Imran Haque, senior vice president of AI and digital sciences at Recursion, a start-up founded in Salt Lake City, Utah, in 2013. Exscientia’s interim CEO, David Hallett, will serve as the company’s science chief. (1601830) SEC Filing S-1 IPO report for the period ending Monday, March 22, 2021. Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. Exscientia shareholders will receive 0. 0 million of shares of its Class A UPDATE: Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability. challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. Essential to decoding biology in our context, is a mindset deeply committed to achieving impact at unprecedented scale through pioneering new industrialized approaches. Today Recursion uses robotic Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster. D. The CEO discussed the company's pipeline growth and its approach to AI and machine learning. - Part 2 Recursion Pharmaceuticals Inc. Other executives include Heather Kirkby, Chief People Officer; Michael Secora, Chief Financial Officer and 3 others. Recursion Pharmaceuticals Statistics. S. On a per-share basis, the Salt Lake City-based company said it had Recursion Pharmaceuticals, headquartered in Salt Lake City, Utah, operates in the biotechnology industry, focusing on biological products. These plans are commonly used by corporate executives to avoid concerns about insider trading. Recursion Pharmaceuticals CEO sells shares worth $871,000. , June 24, 2024--Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with Salt Lake City, Utah, Feb. 's business for stockholders, potential investors, and financial analysts. View detailed RXRX description & address. I’m Chris Gibson, Co-Founder and CEO of Recursion, and I am really excited to welcome you to our first ever Learnings Call here at Recursion. SALT LAKE CITY, May 12, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. Recursion Pharmaceuticals's Co-Founder and CEO is Chris Gibson. Research and Development Insight Details. at Recursion Recursion Pharmaceuticals, Inc. Acknowledging, “we are lucky if we understand 2-3 per cent of biology”, Recursion Pharmaceutical’s co-founder and chief executive Chris Gibson believes the scale of the challenge warrants a different approach. 7729 Recursion shares for each Exscientia share Recursion Pharmaceuticals, Inc. Learn more about its latest innovations and stock performance on CNBC. Come do the most impactful work of SALT LAKE CITY, July 10, 2018 /PRNewswire/ -- Recursion, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover drugs at scale, today announced that the U. Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. The new company will continue using the Recursion name and be led by Recursion co-founder and CEO Chris Gibson. , Co-founder and CEO, will help kick off the 42nd Annual J. Media Contact. Conference Call Hello, readers! Ben Mabey, CTO of Recursion, here with some exciting news to share. The company employs an integrated platform of artificial intelligence, machine learning, and high-throughput biology to uncover new SALT LAKE CITY, Aug. Having raised a $60 million series B round in 2017 and allied with Sanofi and Takeda Pharmaceutical, Recursion In this partnership, Recursion and Bayer may initiate more than ten fibrosis programs with possible development and commercial milestone payments of more than $100 million per program plus royalties on future sales. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Meet the team of ~500 Recursionauts, led by a diverse and experienced executive leadership and board of directors. At Recursion Pharmaceuticals Inc, recent insider activity has drawn attention. (RXRX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key Berlin, Germany and Salt Lake City, USA, Nov. Download the presentation. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. See sources for AI summary Recursion Pharmaceuticals, Inc. It provides products that include a Robotics Platform, Recursion Operating System. , Blake Borgeson, Ph. Get Recursion Pharmaceuticals Inc (RXRX. The company has a broad pipeline across various therapeutic areas Blake Borgeson, a director at Recursion Pharmaceuticals Inc. As a young and innovative company that heavily emphasizes the "tech" portion of the term "biotech," Recursion Pharmaceuticals (RXRX 5. 59 billion. The next estimated earnings date is Thursday, November 7, 2024, before market open. At Recursion, the most compensated executive makes $950,000, annually, and the lowest compensated makes $34,000. , a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6. According to InvestingPro data, Recursion holds a market capitalization of roughly $1. SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. 0 million of shares of its Class A Only a few large pharmaceutical companies have senior executives who are willing to make massive investments in our field. Last updated months ago. Larson and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. (NASDAQ:RXRX - Get Free Report) CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Tuesday, September 10th. Shafique Virani transitioning from Chief Business Officer to Senior Strategic Advisor, offering his expertise to further the As Recursion Pharmaceuticals, Inc. An exciting milestone in our partnership with Roche and Genentech Stay updated with the latest press releases and news from Recursion. Morgan Healthcare Conference with a presentation on Monday, January 8, 2024 at 7:30 am PT. View detailed RXRX. We believe culture drives delivery. 08: MT Recursion Pharmaceuticals, Inc. Experience Recursion Download Day. $94k. RXRX Download Chart Download Data ; Valuation Chart Year: No data Warning Signs Warning Recursion Pharmaceuticals, Exscientia Shares Rise as Companies Agree to Combine Aug. Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer. Skip to content Skip to dynamics feel ever-evolving leaving little room for boredom or mundanity Constant communication and visibility from executives with constant reinforcement of the established values and Complete Recursion Pharmaceuticals Inc. 16% of Recursion Pharmaceuticals Inc (RXRX)’s shares, while financial institutions hold 75. Recursion Pharmaceuticals announced its $12. Salaries, reviews, and more - all posted by employees working at Recursion Pharmaceuticals. Recursion Pharmaceuticals, Inc. Exscientia plc has entered into a definitive agreement for acquisition by Recursion Pharmaceuticals, with the transaction Key Executives. And, despite adding a collaboration with Merck KGaA in September 2023 that could top $1 billion in potential The organizational chart of Recursion Pharma displays its 46 main executives including Chris Gibson, Michael Secora, Ryan Kelly and Kevin Leggat. 68% of Recursion Pharmaceuticals Inc (RXRX)’s shares, while financial institutions hold 77. The average Recursion executive compensation is $239,801 a year. She joins from Johnson & Johnson where Former Goldman Sachs executive to serve as Chairman of Recursion's Board, effective immediately. (NASDAQ:RXRX) CEO Christopher Gibson recently sold a significant amount of company stock, according to the latest SEC filings. Chris Gibson - Co-Founder and Chief Executive Officer Najat Khan Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. 27M), Platinum Investment About Recursion. 0. " Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates Pharmaceuticals is driving the company's vision forward. com, or connect on X (formerly Twitter) and LinkedIn. Recursion has the pipeline disease model which includes Phase II Candidate: Cerebral Cavernous Malformation, Phase I This page offers an in-depth profile of Recursion Pharmaceuticals Inc, including a general overview of the company's business and key management. The mission of Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200. RXRX) on Thursday reported a loss of $97. Free Test. FOLLOW US. The enterprise value is $1. Exscientia Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs. He occupies the position of Chairman of Biohive and Chief Executive Officer & Director at Recursion Pharmaceuticals, Inc. Pay Download Day consisted of presentations on Recursion’s technology, science, pipeline and partnerships, as well as demonstrations of Recursion’s mapping and navigating technology and tours of the company’s highly automated laboratories. . 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Chris Gibson, Ph. See sources for AI summary. prtm yuxk zcxj djnzyt alu ayxqsf txqsjn uije fcmjr bukdp